We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
By Tapan Panchal
LONDON--GlaxoSmithKline PLC (GSK.LN) said Monday that it has sought U.S. Food and Drug Administration approval for a new vaccine for the prevention of shingles, a viral disease characterized by a skin rash with blisters involving a limited area.
The pharmaceutical company has submitted a biologics license application for Shingrix vaccine to the regulator.
The company said regulatory submissions for the vaccine in the European Union and Canada are on track for 2016 and planned for Japan in 2017. The vaccine isn't currently approved for use anywhere in the world.
-Write to Tapan Panchal at tapan.panchal@wsj.com
(END) Dow Jones Newswires
October 24, 2016 02:35 ET (06:35 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions